Literature DB >> 12740234

Steroids for septic shock: back from the dead? (Pro).

Robert A Balk1.   

Abstract

The use of corticosteroids as adjunctive therapy for severe sepsis and septic shock has been a source of controversy for the past 35 years. Despite a wealth of preclinical data supporting both survival and physiologic benefit for early steroid use, the data in human sepsis have been much less convincing. There have even been reports suggesting the potential for harm associated with the administration of early high-dose corticosteroids in patients with severe sepsis and septic shock. Recent trials have reported hemodynamic and survival benefits associated with the use of more physiologic steroid replacement therapy in patients with vasopressor-dependent septic shock. These results coupled with the observation of "relative adrenal insufficiency" in some patients with severe sepsis and septic shock may once again establish a defined role for corticosteroid therapy in the management of severe sepsis and septic shock.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12740234     DOI: 10.1378/chest.123.5_suppl.490s

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  4 in total

1.  Stratification is the key: inflammatory biomarkers accurately direct immunomodulatory therapy in experimental sepsis.

Authors:  Marcin F Osuchowski; Judith Connett; Kathleen Welch; Jill Granger; Daniel G Remick
Journal:  Crit Care Med       Date:  2009-05       Impact factor: 7.598

2.  Congenital tuberculosis: late manifestation of the maternal infection.

Authors:  Priyankar Pal; Apurba Ghosh
Journal:  Indian J Pediatr       Date:  2008-06-08       Impact factor: 1.967

3.  Endogenous and exogenous glucocorticoids in experimental enterococcal infection.

Authors:  Christopher J Papasian; Nilofer Qureshi; David C Morrison
Journal:  Clin Vaccine Immunol       Date:  2006-03

4.  Glucocorticoid Receptor Expression in Peripheral WBCs of Critically Ill Children.

Authors:  Audrey R Ogawa Shibata; Eduardo J Troster; Hector R Wong
Journal:  Pediatr Crit Care Med       Date:  2015-06       Impact factor: 3.624

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.